Table 1.
Baseline characteristics of the 14 patients diagnosed with endometrial cancer or atypical hyperplasia
| Initial diagnosis n (%) | ||
| Atypical hyperplasia | 3 | (21%) |
| Endometrial cancer, G1 | 10 | (71%) |
| Endometrial cancer, G2 | 1 | (7%) |
| Age at diagnosis (years) median (range) | 32.2 | (30.1–47.9) |
| Body mass index (kg/m2) median (range) | 32.8 | (21.6–47.9) |
| Body mass index (kg/m2) n (%) | ||
| < 24.9 kg/m2 | 3 | (21%) |
| 25–29.9 kg/m2 | 3 | (21%) |
| 30–34.9 kg/m2 | 2 | (14%) |
| 35–39.9 kg/m2 | 2 | (14%) |
| ≥ 40 kg/m2 | 4 | (29%) |
| Other risk factors n (%) | ||
| PCOS | 2 | (14%) |
| Diabetes mellitus type II | 3 | (21%) |
| Reason for initial diagnosis n (%) | ||
| Primary infertility | 10 | (71%) |
| Secondary infertility | 4 | (29%) |
| Ectopic pregnancy | 1 | |
| Caesarian section | 2 | |
| Vaginal delivery | 1 | |
| Pelvic imaging n (%) | ||
| Pelvic ultrasound | 14 | (100%) |
| MRI | 10 | (71%) |
| Progestin therapy n (%) | ||
| MPA 500 mg/day | 8 | (57%) |
| MA 160 mg/day | 4 | (29%) |
| MA 320 mg/day | 1 | (7%) |
| Dydrogesteron 10 mg/day | 1 | (7%) |
PCOS Polycystic ovarian syndrome, MPA Medroxyprogesterone acetate, MA Megestrol acetate, MRI Magnetic resonance imaging